Human urine stem cells protect against cyclophosphamide-induced premature ovarian failure by inhibiting SLC1A4-mediated outflux of intracellular serine in ovarian granulosa cells

Abstract excerpt

BACKGROUND: Cyclophosphamide (CTX) is the first-line medication for the treatment of breast cancer, although it potentially leads to severe ovarian dysfunction and even premature ovarian failure (POF). However, the mechanism of CTX-induced POF remains unclear. Mesenchymal stem cell-based therapy has been wildly used for treating numerous diseases. Therefore, our study aims to elucidate the underlying mechanism of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Extracellular vesicles in disease
• Share to Ovarian cancer diagnosis and treatment
• Share to Reproductive Biology and Fertility